Heme oxygenase-1 and gut ischemia/reperfusion injury: A short review

Yu-Feng Liao, Wei Zhu, Dong-Pei Li, Xiao Zhu

INTRODUCTION

Ischemia/reperfusion (I/R) injury of the gut occurs frequently in a variety of clinical settings, including abdominal aortic aneurysm surgery, mesenteric artery occlusion, small bowel transplantation, cardiopulmonary bypass, strangulated hernia, trauma, and shock [1]. The exact mechanisms involved in the pathogenesis of which have not been fully elucidated. Gut I/R injury is associated with substantial morbidity and mortality [2].

The Heme oxygenase (HO) system is the rate-limiting enzyme in heme degradation, resulting in the formation of CO, biliverdin, and free iron. The HO system is believed to confer cytoprotection by inhibiting inflammation, oxidation, and apoptosis, and maintaining microcirculation. HO-1, an inducible form of HO, serves a vital metabolic function as the rate-limiting step in the heme degradation pathway, and affords protection in models of intestinal I/R injury. HO-1 system is an important player in intestinal I/R injury condition, and may offer new targets for the management of this condition.

Abstract

Ischemia/reperfusion (I/R) injury of the gut is a significant problem in a variety of clinical settings and is associated with high morbidity and mortality. Although the mechanisms involved in the pathogenesis of gut I/R injury have not been fully elucidated, it is generally believed that oxidative stress with subsequent inflammatory injury plays an important role. Heme oxygenase (HO) is the rate-limiting enzyme in the catabolism of heme, followed by production of CO, biliverdin, and free iron. The HO system is believed to confer cytoprotection by inhibiting inflammation, oxidation, and apoptosis, and maintaining microcirculation. HO-1, an inducible form of HO, serves a vital metabolic function as the rate-limiting step in the heme degradation pathway, and affords protection in models of intestinal I/R injury. HO-1 system is an important player in intestinal I/R injury condition, and may offer new targets for the management of this condition.
role remains unclear\[4\].

HO-1, as an inducible form, also belongs to a member of the heat shock protein family and is highly inducible by a vast array of stimuli\[5\]. Many studies indicated that the induction of HO-1 plays a significant protective role against inflammatory processes and oxidative tissue injury\[5-7\]. In this review, we focus on the current understanding of the cytoprotective effects observed with the HO system during gut I/R injury. The implications for possible therapeutic manipulation of HO in gut I/R injury are elucidated.

**ISCHEMIA/REPERFUSION INJURY IN GUT**

 Interruption of blood supply results in ischemic injury which rapidly damages metabolically active tissues. Paradoxically, reintroduction of blood flow obtained following ischemia initiates a cascade of events that can potentially worsen the original injury. This effect is known as reperfusion injury\[8\]. The intestine is composed of labile cells that are very susceptible to I/R injury\[9\]. Multiple factors have been shown to be involved in the process of intestinal I/R injury. The primary pathophysiological events of this injury involve microcirculatory flow disturbances caused by the production of reactive oxygen species (ROS). Tissue ischemia and oxidative stress activate families of protein kinases that converge on specific transcriptional factors that regulate the expression of inflammatory genes. The resulting gene products include enzymes \[e.g., inducible nitric oxide synthase (iNOS); phospholipase A\_2, and cyclooxygenase-2 (COX-2)], cytokines \[e.g., tumor necrosis factor α (TNF-α); interleukin-1 (IL-1); interleukin-6 (IL-6)], prostanoids \[e.g., PGE-2], and adhesion molecules \[e.g., intracellular adhesion molecule (ICAM)-1; E-selectin\]. Intestinal I/R injury, which is further amplified by the recruitment of circulating leukocytes, which are known to be key effector cells in causing tissue injury. Furthermore, I/R injury induces widespread endothelial cell apoptosis and the loss of endothelial cells in the vessels serving the organ results in thrombosis directly in the intestine\[10\]. This injury observed during I/R is believed to trigger a systemic inflammatory response leading to multiple organ failure\[17,18\], which frequently involves the lungs and liver\[20\]. Intestinal I/R injury is a complex, multifactorial pathophysiological process, dependent upon an understanding of which the optimal therapeutic approach is aimed at ameliorating I/R injury (Table 1). HO-1 system might be one of the most promising approaches among the potential therapeutic options.

**ROLE OF HO-1 IN ISCHEMIA/REPERFUSION INJURY IN GUT**

 HO-1 is expressed constitutively in normal gastric, intestinal, and colonic mucosa\[22,23\], and is up-regulated in their inflamed tissue\[23\]. Many studies showed that HO-1 is involved in a variety of regulatory and protective cellular mechanisms as a stress-responsive protein\[5,4\]. The normal expression and up-regulation of HO-1 suggest that activation of HO-1 could act as a natural defensive mechanism to alleviate inflammation and tissue injury in the gastrointestinal tract\[24,25\]. HO has been shown to have potent cytoprotective effects on intestinal I/R injury as well\[26\]. For example, induction of HO-1 by cobalt-protoporphyrin administration before intestinal I/R resulted in a significant reduction of intestinal tissue injury\[27\]. Another enhancer \(\text{pyrrolidine dithiocarbamate}\) of HO production improves intestinal microvascular perfusion and attenuates I/R injury of the intestine, possibly via HO production\[28\]. Similarly, administration with a HO inducer \(\text{hematin}\) results in lessened mucosal injury and improved intestinal transit following gut I/R\[29\]. Glutamine protects the intestine from warm ischemic injury, which was considered to be associated with inducible HO-1 expression through the interaction with cellular antioxidative activity and the inhibition of cytokines\[30\]. Several studies demonstrated that intraischemic hypothermia, hypertonic saline resuscitation, and whole-body hyperthermia decrease inflammation and protect against intestinal injury in a model of gut I/R\[31-33\]. Administration of IL-2, an immunoregulatory cytokine, resulted in clinical improvement of the study animals after intestinal I/R\[34\]. These protective interventions were associated with the induction of HO-1. Postischemic leukocyte-endothelial cell adhesive interactions are prevented by 5-aminomimidazole-4-carboxamide 1-beta-D-ribofuranoside preconditioning 24 h prior to I/R in the small intestine by HO-dependent mechanisms\[35\]. Furthermore, ischemic preconditioning of the intestine might prove to be an effective strategy for the amelioration of I/R injury, in which HO is involved\[36,37\]. Pretreatment with Radix Paeoniae Rubra\[38\], or the anticancer drug doxorubicin\[20\] can attenuate acute lung injury resulting from intestinal I/R. These results demonstrate that HO-1 is implicated in cytoprotection and may be an effective agent for the treatment of gut I/R.

**MECHANISMS OF ACTION**

There is increasing evidence that HO-1 plays an important protective role in gut I/R injury. There are four factors that could be responsible for the protection of HO-1 in intestinal I/R, including: (1) removal of free heme; (2) CO; (3) biliverdin/bilirubin; and (4) Fe\(^{3+}\).

**REMOVAL OF FREEHEME**

Heme, an essential iron chelate, is a potentially damaging species that not only provides a lipophilic form of iron, but also can directly attack and impair a multiplicity of intracellular targets\[39\]. production increases under conditions of oxidant stress, especially in I/R injury\[39,40\]. HO-1 is the key enzyme in heme degradation and plays a key role in regulating the intracellular heme level. HO-1 activity leads to rapid removal of free heme. Thus, in order
to prevent heme from both extracellular and intracellular sources reacting and producing ROS, the heme degradation step is an important consideration in the cytoprotection afforded by the HO system.  

**CO**

CO is one of the three products of heme degradation by HO-1 and has profound effects as a signaling molecule that culminates in anti-inflammatory, antiapoptotic, and vasodilating effects. A number of studies have revealed that CO mediates potent cytoprotective and anti-inflammatory effects in models of I/R injury of the heart, lung, kidney, and liver. Some studies demonstrate that the efficacy of CO gas inhalation for the prevention of cold intestinal I/R injury using a small intestinal transplantation model, in which CO is able to effectively inhibit an early up-regulation of pro-inflammatory mediators such as IL-6, IL-1, TNF-α, ICAM-1, iNOS, and COX-2. It has been reported that pre-treatment with CO-releasing molecules also markedly reduced intestinal inflammation induced by surgical manipulation of the small intestine or by occluding the superior mesenteric artery. Similarly, one study showed that cold storage in a preservation solution that was bubbled with 5% CO significantly reduced I/R injury associated with intestinal transplantation, which reduced inflammatory mediator up-regulation and improved graft blood flow. Moreover, CO-treated animals showed early up-regulation of the anti-apoptotic molecule Bel-2, and down-regulation of the proapoptotic signal Bax, and reduced in vivo apoptosis of both vascular endothelial cells and intestinal epithelial cells. The protective effects of CO are arbitrated by activating one or both of the two key signaling pathways. One of the pathways is soluble guanylate cyclase/cyclic guanosine monophosphate and the other one is the p38 mitogen-activated protein kinase pathway which transduces oxidative stress and inflammatory signaling, through which CO exerts significant cytoprotection due to its anti-inflammatory, vasodilating, and anti-apoptotic properties in gut I/R injury.

## BILIVERDIN/BILIRUBIN

HO degrades heme into equimolar quantity of biliverdin. Biliverdin is, in turn, very rapidly converted to bilirubin by the enzyme biliverdin reductase. Biliverdin and its reduced product, bilirubin, scavenge various ROS and are hence considered potent antioxidants which have been shown to confer cytoprotection against oxidative stress conditions in various cell types. Several studies have also demonstrated that the administration of biliverdin and/or bilirubin is potently cytoprotective in I/R injury of the liver and heart, and in organ transplantation. Evidence from an experimental small intestinal I/R injury model in rats describes a protective effect for bilirubin, in which the bilirubin is infused into the jejunal muscularis in rat syngeneic small intestinal transplants. These results suggest that bilirubin possesses complex immune-modulatory and antioxidant effects.

### Fe²⁺

Though HO activity is generally associated with cellular protection, Fe²⁺, the third product of heme decomposition, participates in the Fenton reaction to promote the generation of ROS and is believed to have potential deleterious effects. Increased iron levels, on the one hand, can upregulate an iron-transporter pump that removes intracellular Fe²⁺ from the cell. On the other hand, iron release from HO activity induces the expression of ferritin (an iron storing protein). Expression of ferritin was originally reported to protect endothelial cells against oxidant damage in vitro. In addition, over-expression of H-ferritin (heavy chain ferritin) has also been shown to protect cultured endothelial cells from undergoing apo-

### Table 1  The role of heme oxygenase-1 for the protection of intestinal ischemia/reperfusion injury

| Treatment | I/R model | Ref. |
|-----------|-----------|------|
| HO-1 | Glutamine | Warm ischemia | [30] |
| Ischemic preconditioning | Resuscitation after shock | [37] |
| Doxorubicin | Warm ischemia | [20] |
| Hypothermia | Warm ischemia | [32] |
| IL-2 | Warm ischemia | [34] |
| Hemin | Warm ischemia | [29] |
| Hypertonic saline | Warm ischemia | [31] |
| Pyrolidine dithiocarbamate | Warm ischemia | [28] |
| Hyperthermia | Warm ischemia | [33] |
| Ischemic preconditioning | Warm ischemia | [36] |
| Cobalt-protoporphyrin | Warm ischemia | [27] |
| Ischemic preconditioning | Endotoxic shock | [18] |
| Radix Paeoniae Rubra | Warm ischemia | [30] |
| AICAR preconditioning | Warm ischemia | [35] |

**CO**

- **Gas inhalation**
  - Intestinal transplants [11]
  - Intestinal transplants [13]
  - Intestinal transplants [14]
  - Intestinal transplants [47]
  - Intestinal transplants [12]

- **CORM preconditioning**
  - Warm ischemia [48]

**Biliverdin/bilirubin**

- **Bilirubin**
  - Warm ischemia [60]

- **Biliverdin**
  - Warm ischemia [61]

AICAR: 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside; CORM: CO-releasing molecules; IL-2: Interleukin-2; I/R: Ischemia/reperfusion; HO: Heme oxygenase.
Heme oxygenase and gastrointestinal injury

Figure 1 Schematic demonstration of the heme oxygenase-1 system and its biologic activities in gut ischemia/reperfusion injury. HO: Heme oxygenase.

- Anti-inflammation, anti-apoptosis, antioxidation, vasodilating
- Tissue protection

CLINICAL EVIDENCE
As we mentioned above, the HO-1 system plays an important role in the cytoprotective process, up-regulation of which seems to be a potential therapeutic option for gut I/R injury. As far as we know, there have been no definitive trials designed to evaluate the efficacy of chemical HO-1 inducers in the clinical setting. Hemin, as an inducer of HO-1, has been used extensively in experimental studies, but has only been used by physicians experienced in the management of porphyrias clinically. However, there are increasing reports showing that hemin-induced HO-1 activity is a host defense mechanism in different animal models, such as the thrombosis vascular model[65], in liver I/R injury[66], acute pancreatitis with multi-organ failure[67-69], human immunodeficiency virus-1 infection[70], and spontaneously hypertension[71]. Such disease states share part or common physiopathological process with gut I/R injury, which suggests that hemin could offer a therapeutic benefit for gut I/R injury. A richer understanding of the cytoprotective mechanisms of hemin therapy will be necessary, which will also pave the way for clinical application in the treatment of gut I/R injury.

CONCLUSION
Intestinal I/R injury is a complex, multifactorial pathophysiological process. Despite its complexity, the HO-1 system, owing to its antioxidative, anti-inflammatory, anti-apoptosis, and potent cytoprotective properties (Figure 1), may serve as promising potential therapeutic options for intestinal I/R injury.

The modulation of HO-1 expression using genetic or pharmacological strategies may offer therapeutic strategies for intestinal I/R injury. Furthermore, HO-1-related molecules, including CO and biliverdin/bilirubin, might be employed as drugs in the management of intestinal I/R injury. More importantly, regulating the HO-1 system with different agents has already been demonstrated as important for attenuating I/R injury in other organs including the brain, liver, and kidney[65,72-74]. It is reasonable to assume that such a mechanism could also be operative in intestinal I/R injury. Research focused on the underlying mechanisms for the observed effects of HO-1 and its products will be necessary before their use can be evaluated in clinical applications for the prevention and/or treatment of human diseases such as intestinal I/R injury.

REFERENCES
1 Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001; 94: 1133-1138 [PMID: 11465607 DOI: 10.1097/00000542-200106000-00030]
2 Grootjans J, Lenaerts K, Deriks JP, Matthijsen RA, de Bruijn AP, van Bijnen AA, van Dam RM, Dejong CH, Buurman WA. Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a new translational model. Am J Pathol 2010; 176: 2283-2291 [PMID: 20348235]
3 Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-554 [PMID: 9131265 DOI: 10.1146/annurev.pharm.tox.37.1.517]
4 McCoubrey WK, Huang TJ, Maines MD. Isolation and characterization of a cDNA from the rat brain that encodes heme oxygenase-3. Eur J Biochem 1997; 247: 725-732 [PMID: 9266719 DOI: 10.1111/j.1432-1033.1997.00725.x]
5 Fan W, Huang F, Zhu X, Li D, Fu S, He H. The heme oxygenase system and oral diseases. Oral Dis 2011; 17: 252-257 [PMID: 20964760 DOI: 10.1111/j.1601-0825.2010.01732.x]
6 Zhu X, Fan WG, Li DP, Kung H, Lin MC. Heme oxygenase-1 system and gastrointestinal inflammation: a short review. World J Gastroenterol 2011; 17: 4283-4288 [PMID: 22090784 DOI: 10.3748/wjg.v17.i38.4283]
7 Bae GS, Kim MS, Park KC, Koo BS, Jo IJ, Choi SB, Lee DS, Kim YC, Kim TH, Seo SW, Shin YK, Song HJ, Park SJ. Effect of biologically active fraction of Nardostachys jatamansi on cerulein-induced acute pancreatitis. World J Gastroenterol 2012; 18: 3223-3234 [PMID: 22783046 DOI: 10.3748/wjg.v18.i25.3223]
8 Stallion A, Kou TD, Miller KA, Dahms BB, Dugdeon DL, Levine AD. IL-10 is not protective in intestinal ischemia reperfusion injury. J Surg Res 2002; 105: 145-152 [PMID: 12121701]
9 Yamamoto S, Tanabe M, Wakabayashi G, Shimazu M, Matsimoto K, Kitajima M. The role of tumor necrosis factor-a and interleukin-1beta in ischemia-reperfusion injury of the rat small intestine. J Surg Res 2001; 99: 134-141 [PMID: 11421615 DOI: 10.1006/jse.2001.6106]
10 Scott JR, Gray DK, Bihari A, Badhwar A, Zhang X, Shan P, Lee PJ, Chakrabarti S, Harris KA, Potter RF. Heme oxygenase modulates small intestine leukocyte adhesion following hindlimb ischemia/reperfusion by regulating the expression of intercellular adhesion molecule-1. Crit Care Med 2005; 33: 2560-2570 [PMID: 16276181 DOI: 10.1097/01.CCM.0000186765.61268.FC]
11 Nakao A, Kimizuka K, Stolz DB, Neto JS, Kaizu T, Choi AM, Uchiyama T, Zuckerbraun BS, Nalesnik MA, Otterbein LE, Murase N. Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Ann J Pathol
Liao YF et al. Heme oxygenase and gastrointestinal injury

2003; 163: 1587-1598 [PMID: 14507665]

27 Wasserberg N, Pileggi A, Salgar SK, Ruiz P, Ricordi C, Inverardi L, Tzakis AG. Heme oxygenase-1 upregulation protects against intestinal ischemia/reperfusion injury: a laboratory based study. Int J Surg 2007; 5: 216-224 [PMID: 17660127 DOI: 10.1016/j.ijsu.2006.10.001]

28 Mallick IH, Yang WX, Winslet MC, Seifalian AM. Pyridoline dithiocarbamate reduces ischemia-reperfusion injury of the small intestine. World J Gastroenterol 2005; 11: 7308-7313 [PMID: 16437633]

29 Attuwaybi BO, Kozar RA, Moore-Olufemi SD, Sato N, Hassoun HT, Weisbrodt NW, Moore FA. Heme oxygenase-1 induction by hemin protects against gut ischemia/reperfusion injury. J Surg Res 2004; 118: 53-57 [PMID: 15093717 DOI: 10.1016/j.jss.2004.01.010]

30 Tamaki T, Konoeda Y, Yasuhara M, Tanaka M, Yokota N, Hayashi T, Katori M, Uchida Y, Kawamura A. Glutamine-induced heme oxygenase-1 protects intestines and hearts from warm ischemic injury. Transplant Proc 1999; 31: 1018-1019 [PMID: 10083452]

31 Attuwaybi BO, Kozar RA, Gates KS, Moore-Olufemi S, Sato N, Weisbrodt NW, Moore FA. Hypertonic saline prevents inflammation, injury, and impaired intestinal transit after gut ischemia/reperfusion by inducing heme oxygenase 1 enzyme. J Trauma 2004; 56: 749-758; discussion 758-759 [PMID: 15187737]

32 Attuwaybi BO, Hassoun HT, Zou L, Kozar RA, Kone BC, Weisbrodt NW, Moore FA. Hypothermia protects against gut ischemia/reperfusion-induced impaired intestinal transit by inducing heme oxygenase-1. J Surg Res 2003; 115: 48-55 [PMID: 14527727]

33 Sakamoto N, Kokura S, Okuda T, Hattori T, Kada T, Isozaki Y, Nakabe N, Handa O, Takagi T, Ishikawa T, Naito Y, Yoshida N, Yoshikawa T. Heme oxygenase-1 (Hsp32) is involved in the protection of small intestine by whole body mild hyperthermia from ischemia/reperfusion injury in rat. Int J Hyperthermia 2005; 21: 603-614 [PMID: 16304713 DOI: 10.1080/02652072.2005.10503613]

34 Nüssler NC, Müller AR, Weidenbach H, Vergopoulos A, Platzer KP, Volk HD, Neuhaus P, Nüssler AK. IL-10 increases tissue injury after selective intestinal ischemia/reperfusion. Ann Surg 2003; 238: 49-58 [PMID: 12832965 DOI: 10.1097/01.\_ske.0000074962.26047.\_d]

35 Gaskin FS, Kamada K, Yusof M, Durante W, Gross G, Korthuis RJ. AICAR preconditioning prevents postischemic leukocyte rolling and adhesion: role of K(ATP) channels and heme oxygenase. Microcirculation 2009; 16: 167-176 [PMID: 19152177 DOI: 10.1080/10739860802355897]

36 Mallick IH, Yang W, Winslet MC, Seifalian AM. Protective effects of ischemic preconditioning on the intestinal mucosal microcirculation following ischemia-reperfusion of the intestine. Microcirculation 2005; 12: 615-625 [PMID: 16284053 DOI: PIIH11061H1531R616]

37 Tamion F, Richard V, Lacouvee Y, Thilliez C. Intestinal preconditioning prevents systemic inflammatory response in hemorrhagic shock. Role of HO-1. Am J Physiol Gastrointest Liver Physiol 2002; 283: G408-G414 [PMID: 12181899]

38 Chen C, Zhang F, Xia YZ, Lin H, Mo AS. Protective effects of pretreatment with Radix Paoniae Rubra on acute lung injury induced by intestinal ischemia/reperfusion in rats. Chin J Traumatol 2008; 11: 37-41 [PMID: 18262090 DOI: 10.1016/S1008-1275(08)60008-3]

39 Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. Free Radic Biol Med 2000; 28: 289-309 [PMID: 11281297]

40 Katori M, Anselmo DM, Busuttil RW, Kupiec-Weglinski JW. A novel strategy against ischemia and reperfusion injury: cytoprotection with heme oxygenase system. Transpl Immunol 2002; 9: 227-233 [PMID: 12180835]
Liao YF et al. Heme oxygenase and gastrointestinal injury

41 Ryder SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650 [PMID: 16601269 DOI: 86/2/583]

42 Takagi T, Naito Y, Uchiyama K, Suzuki T, Hitani A, Mizusuma K, Tsuehi H, Hayashi N, Handa O, Ishikawa T, Yagi N, Kobuka S, Ichikawa H, Yoshikawa T. Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice. Dig Dis Sci 2011; 56: 1663-1671 [PMID: 21086613 DOI: 10.1007/s10020-010-1484-y]

43 Kohimoto J, Nakao A, Sugimoto R, Wang Y, Zhan J, Ueda H, McCurry KR. Carbon monoxide-saturated preservation solution protects lung grafts from ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2008; 136: 1067-1075 [PMID: 18954651]

44 Lavitrano M, Smolenski RT, Musumeci A, Maccherini M, Safran H, Kwan R, Yang AL, Morgan ME, Akhtar E, Liao YF. Is there a Role for Biliverdin Reductase? Biochem Soc Symp 2004; (71): 177-192 [PMID: 15777021]

45 Fondevila C, Shen XD, Tsuchiyashi S, Yamashita K, Ciszmadia E, Lassman C, Busuttil RW, Kupiec-Weglinski JW, Bach FH. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 2004; 40: 1333-1341 [PMID: 15565657 DOI: 10.1002/hep.20480]

46 Foresti R, Green CJ, Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem Soc Trans 2004; (32): 177-192 [PMID: 15777021]

47 Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046 [PMID: 5029864 DOI: 10.1126/science.3029960]

48 Foresti R, Green CJ. Biliverdin Reductase. Front Pharmacol 2012; 3: 30 [PMID: 22438843 DOI: 10.3389/fphar.2012.00030]

49 Ollinger R, Wang H, Yamashita K, Wiegell B, Thomas M, Margreiter R, Bach FH. Therapeutic applications of bilirubin and biliverdin in transplantation. Transplant Rev Sziget 2007; 9: 2175-2185 [PMID: 17919067 DOI: 10.1089/ars.2007.1807]

50 Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol Heart Circ Physiol 2000; 278: H1643-H1651 [PMID: 10666097]

51 Blei GF, Basu-Moddak S, Walthner C, Tyrrell RM. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA 1994; 91: 2607-2610 [PMID: 8146161 DOI: 10.1073/pnas.91.7.2607]

52 Bala G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercellotti GM. Ferritin: a cytoprotective antioxidant regulating cellular iron. Cell Bio 1999; 1: 152-157 [PMID: 10599901]

53 De Backer O, Elinek, Blanckaert B, Leybaert L, Motterlini R, Lefebvre RA. Water-soluble CO-releasing molecules reduce the development of postoperative ileus modulates of MAPK/HO-1 signalling and reduction of oxidative stress. Gut 2009; 58: 347-356 [PMID: 19022916 DOI: gut.2008.155481]

54 Nakao A, Otterbein LE, Overhaus M, Sarady JK, Tsung A, Kimizuka K, Nalesnik MA, Kaizu T, Uchiyama T, Liu F, Murase N, Bauer AJ, Bach FH. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 2004; 127: 595-606 [PMID: 15309591]

55 Jansen T, Daiber A. Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase? Front Pharmacol 2012; 3: 30 [PMID: 22438843 DOI: 10.3389/fphar.2012.00030]
Devadas K, Dhawan S. Hemin activation ameliorates HIV-1 infection via heme oxygenase-1 induction. *J Immunol* 2006; 176: 4252-4257 [PMID: 16547262 DOI: 176/7/4252]

Shamloul R, Wang R. Monitoring circulatory heme level in hemin therapy for lowering blood pressure in rats. *Cell Mol Biol (Noisy-le-grand)* 2005; 51: 507-512 [PMID: 16309573 DOI: 507]

Hoetzel A, Schmidt R. Regulatory role of anesthetics on heme oxygenase-1. *Curr Drug Targets* 2010; 11: 1495-1503 [PMID: 20704551 DOI: B8P/CDT/E-Pub/00145]

Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, Zheng W, Elger M, Fiebeler A, Fliser D, Luft FC, Haller H. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. *Am J Pathol* 2007; 170: 1192-1199 [PMID: 17392159]

Tsuchihashi S, Fondevila C, Kupiec-Weglinski JW. Heme oxygenase system in ischemia and reperfusion injury. *Ann Transplant* 2004; 9: 84-87 [PMID: 15478901]

**P-Reviewers** Camara CR, Kondo T, Wiley JW  **S-Editor** Gou SX  **L-Editor** Rutherford A  **E-Editor** Zhang DN